RxDoctor Payments Data

Todd Brodie, MD

Endocrinology, Diabetes & Metabolism · Naples, FLNPI 1003880170

Payments from drug & device makers

$6,631in general payments, 2019–2025

Across 198 payments — averaging $33.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$958
  • Lilly USA, LLC$604
  • Novo Nordisk$548
  • Xeris Pharmaceuticals, Inc.$477
  • Corcept Therapeutics$416
  • Radius Health, Inc.$376
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$6,56199%
  • Education$691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,631 in reported general payments places this provider in the 55th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida

Medicare billing

Part B allowed, 2024
$204,368
Medicare patients
224
Services billed
4,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StrensiqAsfotase Alfa12$1,779,149
KorlymMifepristone13$429,306
MounjaroTirzepatide183$227,671
OzempicSemaglutide122$198,080
TrulicityDulaglutide80$130,887
JardianceEmpagliflozin55$92,078
FarxigaDapagliflozin Propanediol30$34,129
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$25,992
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$24,820
Tresiba Flextouch U-100Insulin Degludec35$23,834
Repatha SureclickEvolocumab28$20,927
SynthroidLevothyroxine Sodium131$16,256
XyostedTestosterone Enanthate11$13,504
FiaspInsulin Aspart (Niacinamide)11$9,152
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt12$8,187

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaStrensiq, Farxiga$189$1,813,27742 claims
Corcept TherapeuticsKorlym$416$429,30613 claims
Lilly USA, LLCMounjaro, Trulicity$604$358,558263 claims
Novo NordiskOzempic, Fiasp$548$207,232133 claims
Boehringer IngelheimJardiance$101$92,07855 claims
Antares Pharma, Inc.Xyosted$15$13,50411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

Other endocrinology, diabetes & metabolism in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →